BAX — Baxter International Inc.

Baxter International Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Global Sales: $2.7 billion, up 3% year-over-year (YoY) on a reported basis, but down 1% on an organic basis.
• Adjusted Earnings: $0.36 per diluted share, a decrease of 35% compared to $0.55 in Q1 2025.
• Adjusted Gross Margin: 36.8%, down 500 basis points YoY.
• Adjusted Operating Margin: 11%, down 390 basis points YoY.
• Free Cash Flow: $76 million, a significant improvement from negative $221 million in Q1 2025.

2. Strategic Updates and Business Highlights

• Leadership Transition: Anita Zielinski is serving as Interim CFO while a search for a permanent successor is underway.
• Turnaround Focus: CEO Andrew Hider emphasized stabilizing the business, strengthening the balance sheet, and driving continuous improvement through the Baxter Growth and Performance System (GPS).
• Product Innovations: Successful launches include the Dynamo smart hospital stretcher and the IV Verified Line labeling system, with ongoing development in AI-integrated solutions.
• Market Performance: Advanced Surgery segment grew 10%, while Medical Products & Therapy (MPT) faced challenges due to Novum LVP shipment holds.

3. Forward Guidance and Outlook

• 2026 Sales Growth: Reiterated guidance for total sales growth to be flat to 1% on a reported basis, with organic sales expected to remain flat.
• Segment Expectations:
  • MPT: Flat to slightly up organic sales, impacted by Novum shipment holds.
  • Healthcare Systems & Technology (HST): Low single-digit growth anticipated, particularly in the second half.
  • Pharmaceuticals: Expected to be approximately flat, with ongoing challenges in Injectables and Anesthesia.
• Operating Margin Guidance: Expected to range between 13% to 14% for the full year.

4. Bad News, Challenges, or Points of Concern

• Declining Earnings: Adjusted earnings per share significantly decreased YoY due to cost pressures and unfavorable comparisons.
• Tariff and Cost Pressures: Anticipated full-year impact from tariffs estimated at $80 million, contributing to margin pressures.
• Novum LVP Issues: Ongoing shipment and installation holds remain a significant concern, with potential customer returns factored into guidance.
• Supply Chain Challenges: Continued supply constraints in the Pharmaceuticals segment, particularly in Injectables, are expected to persist into 2027.

5. Notable Q&A Insights

• Market Dynamics: Analysts questioned the sustainability of Q1 trends, particularly regarding Novum returns and the impact of macroeconomic factors like inflation and supply chain disruptions.
• CFO Search: The search for a new CFO is progressing well, with a focus on finding a candidate who understands execution and the business.
• Innovation Strategy: Hider emphasized a disciplined approach to innovation, focusing on customer needs and operational efficiency, with several new product launches expected to drive future growth.
• Confidence in Recovery: Management expressed cautious optimism about the second half of 2026, expecting improvements in organic sales growth and operating margins as the company addresses current challenges.

Overall, while Baxter International is facing significant headwinds, particularly related to supply chain issues and the Novum LVP situation, the company is committed to a turnaround strategy with a focus on innovation and operational improvements.